Title: Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot study
Authors: SCHEIDHAUER KlemensSEIDL C.MORGENSTERN AlfredBRUCHERTSEIFER FrankAPOSTOLIDIS ChristosAUTENRIETH MichaelKURTZ FESSLER M.SCHWAIGER M.SENEKOWITSCH-SCHMIDTKE R.
Citation: JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 639
Publisher: SOC NUCLEAR MEDICINE INC
Publication Year: 2014
JRC N°: JRC88670
ISSN: 0161-5505
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC88670
Type: Articles in periodicals and books
Abstract: Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate therapeutic efficacy of the α-emitter radioimmunoconjugate in bladder cancer patients.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.